
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ArgRS CRISPR/Cas9 KO Plasmid (m) | sc-430545 | 20 µg | $397.00 |
Mouse Rars encodes arginyl-tRNA synthetase (ArgRS), a core cytosolic aminoacyl-tRNA synthetase that ligates arginine to its cognate tRNA to support accurate translation and proteome homeostasis. By controlling the supply of charged tRNA^Arg, ArgRS influences translational fidelity, stress responses linked to amino acid availability, and downstream effects on cell growth and differentiation programs. Altered aminoacyl-tRNA synthetase function has been associated with neurodevelopmental and neuromuscular phenotypes, immune dysregulation, and proliferative defects, making Rars a relevant node for investigating how translation-linked perturbations reshape cellular states. In mouse models, Rars disruption provides a direct route to interrogate essential gene function, compensatory tRNA synthetase networks, and context-dependent sensitivity to proteostasis stress.
ArgRS CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Rars gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Rars together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Rars open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ArgRS protein expression.
This CRISPR knockout system enables efficient generation of Rars-deficient cell models for investigation of ArgRS signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.